Bortezomib
- PDF / 169,072 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 50 Downloads / 168 Views
1 S
Neuropathy: case report In a prospective observational study involving 32 patients, one patient [age and sex not stated] was described, who developed grade II neuropathy during treatment with bortezomib for multiple myeloma. The patient who had multiple myeloma presented with renal failure and was placed on dialysis. The patient received IV bortezomib 1.3 mg/m2 along with dexamethasone weekly for myeloma. The patient received total 4 cycles and each cycle consisted of 4 weeks treatment. However, during treatment, the patient developed grade II neuropathy as a side effect of bortezomib. Therefore, the dose of bortezomib was reduced [duration of treatment to reaction onset and outcome not stated]. Pandey A, et al. Short Term Renal Outcome of Bortezomib Based Therapy in Patients with Multiple Myeloma Requiring Dialysis. Indian Journal of Nephrology 30: 213-214, 803501756 No. 3, 2020. Available from: URL: http://doi.org/10.4103/ijn.IJN_229_18
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
